Phibro Animal Health Corporation · NASDAQ:PAHC
Phibro Animal Health — Q2 2026 Earnings Presentation
9 slides from Phibro Animal Health's earnings presentation, Feb 5, 2026
Slide 1: Phibro Animal Health Corporation Financial Results Fiscal Year 2026 Second Quarter
Phibro Animal Health Corporation Webcast and Conference Call February 5, 2026 U.S. toll-free +1.888.330.2022 International toll +1.365.977.0051 Conference ID: 3927884 Financial Results Fiscal Year 2026 Second Quarter Ended December 31, 2025 February 5, 2026 Webcast and Conference Call
Slide 2: Important Information
Important Information Cautionary Statement Regarding Forward-Looking Statements This communication contains forward-looking statements that are subject to risks and uncertainties, including with respect to any future debt and leverage levels. All statements other than statements of historical or cur
Slide 3: Key Themes
Key Themes Strong Continued Sales FY2026 Full Year Performance in Momentum Guidance Animal Health Q2 Total Consolidated sales and Q2 Total Animal Health sales Updated 2026 guidance adjusted EBITDA growth of 21% and adjusted EBITDA growth of • Net sales of $1.450 and 41% 26% and 41% billion to $1.500
Slide 4: Financial Performance - Consolidated
Financial Performance - Consolidated Second Quarter, Year-on-Year comparison $ in millions, except per share data Q2 Q2 YOY FY25 FY26 %∆ Consolidated Net Sales $ 309.3 $ 373.9 21% Net Income $ 3.2 $ 27.5 NA Diluted EPS $ 0.08 $ 0.67 NA Adjusted EBITDA $ 48.2 $ 68.1 41% Adjusted Net Income $ 22.3 $ 3
Slide 5: Financial Performance – Animal Health
Financial Performance – Animal Health Second Quarter, Year-on-Year comparison $ in millions Q2 Q2 YOY FY25 FY26 %∆ Animal Health Net Sales $ 229.4 $ 290.0 26% MFAs & other Legacy 113.6 108.0 (5%) MFAs & other Z-Product 36.7 94.1 156% Total MFA & other 150.3 202.1 34% Nutritional specialties 45.9 50.
Slide 6: Financial Performance – Other Segments
Financial Performance – Other Segments Second Quarter, Year-on-Year comparison $ in millions Q2 Q2 YOY FY25 FY26 %∆ Mineral Nutrition Net Sales $ 63.3 $ 68.9 9% Adj. EBITDA $ 5.7 $ 6.4 12% Adj. EBITDA Margin 9.0% 9.2% +20 bps Performance Products Net Sales $ 16.6 $ 15.0 (10%) Adj. EBITDA $ 1.9 $ 0.8
Slide 7: Key Capitalization Metrics
Key Capitalization Metrics December 31, 2025 Free cash flow was $47 million for the TTM -- positive cash from operating activities Free Cash Flow (1) of $93 million, less capital expenditures of $(46) million. Cash and cash equivalents of $74.5 million 3.1x gross leverage ratio; $737 million total d
Slide 8: Financial Guidance – Phibro
Financial Guidance – Phibro Fiscal Year 2026 $ in millions, except earnings per share (EPS) data FY 2025 FY 2026 FY 2026 Previous Updated Actual Low High Low High Consolidated Net Sales $ 1,296 $ 1,425 $ 1,475 $ 1,450 $ 1,500 Net Income $ 48 $ 75 $ 85 $ 85 $ 95 Diluted EPS $ 1.19 $ 1.83 $ 2.08 $ 2.0
Slide 9: Q&A
PAHC Company Overview Q&A 9 February 5, 2026 Webcast and Conference Call